Cardiovasc Revasc Med
November 2024
Background: Chronic limb-threatening ischemia (CLTI) is associated with increased risk of major adverse cardiac and limb events (MACLE). In patients with peripheral arterial disease (PAD), evolocumab is associated with decreased MACLE, improved maximal walking time, increased vascular flow-mediated dilation (FMD), and decreased carotid intima-media thickness (IMT). We investigated the additive effect of evolocumab in patients with CLTI on maximally tolerated lipid lowering therapy after an index revascularization for non-healing wounds.
View Article and Find Full Text PDFJ Investig Med High Impact Case Rep
November 2024
PLOS Glob Public Health
November 2024
Eur J Case Rep Intern Med
September 2024